Search - tctmd.com

Displaying 961 - 980 of 1179

Sort: Relevancy | Date

News Daily News

Bleeding Score Helps Clinicians Target PCI Patients Best Suited for Bivalirudin

Caitlin E. Cox

March 09, 2013

Presentation PCI Outcomes 2013

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Presenter: Dominick J. Angiolillo

March 07, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

Presentation

Preprocedural Estimate of Individualized Bleeding Risk Impacts Physicians’ Bivalirudin Use During PCI

Presenter: S. C. Rao

March 05, 2013

News Daily News

Un Subestudio del AIDA STEMI No Confirma Ventaja alguna para el Abciximab Intracoronario

February 27, 2013

News Daily News

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

February 27, 2013

Presentation

Intracoronary Compared with IV Bolus Abciximab Application During Primary PCI in STEMI

Presenter: I. Eitel

February 26, 2013

News Daily News

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

February 25, 2013

News Daily News

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

February 25, 2013

Presentation

High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing PCI

Presenter: 147520|Massimo Leoncini

February 24, 2013

Presentation TCT 2013

Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI

Presenter: Subhash Banerjee, Rick Weideman, Bertis Little, Mark Weideman, Jennifer Gunter, Kevin Kelly, Emmanouil Brilakis

January 31, 2013

Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci

January 31, 2013

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

News Daily News

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Jason Kahn

January 22, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Jason Kahn

January 22, 2013

News Daily News

Prasugrel Reloading Feasible After Clopidogrel Pretreatment in ACS Patients

Yael L. Maxwell

January 13, 2013

News Daily News

Las Recargas con Prasugrel son Viables tras un Pretratamiento con Clopidogrel en Pacientes víctimas de un SCA

Yael L. Maxwell

January 13, 2013

Presentation

Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in ACS Patients Undergoing PCI

Presenter: J.P. Loh

January 09, 2013

News Daily News

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

L.A. McKeown

December 19, 2012

News Daily News

Pretratamiento con Clopidogrel Reduce los Episodios Cardíacos pero No la Mortalidad tras una PCI

Yael L. Maxwell

December 19, 2012

Advertisement

Bleeding Score Helps Clinicians Target PCI Patients Best Suited for Bivalirudin

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Preprocedural Estimate of Individualized Bleeding Risk Impacts Physicians’ Bivalirudin Use During PCI

Un Subestudio del AIDA STEMI No Confirma Ventaja alguna para el Abciximab Intracoronario

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

Intracoronary Compared with IV Bolus Abciximab Application During Primary PCI in STEMI

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing PCI

Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

Prasugrel Reloading Feasible After Clopidogrel Pretreatment in ACS Patients

Las Recargas con Prasugrel son Viables tras un Pretratamiento con Clopidogrel en Pacientes víctimas de un SCA

Safety of Reloading Prasugrel in Addition to Clopidogrel Loading in ACS Patients Undergoing PCI

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

Pretratamiento con Clopidogrel Reduce los Episodios Cardíacos pero No la Mortalidad tras una PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content